Humacyte, Inc.
Humacyte, Inc. (HUMA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · HUMA · as of Sep 30, 2025
Ownership Breakdown
150
Institutional Holders
▼ 15 vs Q2
$79.87M
Total Inst. Value
▼ $39.18M vs Q2
168.00M
Shares Outstanding
freeFloat 82.21%
45.87M
13F Shares Held
▼ 11.10M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
HUMA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 9.90M | 6.37% | 6.37% | $17.23B | Nov 12, 2025 | ▼ 43.7K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 7.52M | 4.84% | 4.84% | $13.08B | Nov 7, 2025 | ▲ 520.4K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.10M | 1.99% | 1.99% | $5.39B | Nov 12, 2025 | ▲ 147.7K |
STATE STREET CORP biological products, (no diagnostic substances) | 2.41M | 1.55% | 1.55% | $4.19B | Nov 14, 2025 | ▼ 1.98M |
MORGAN STANLEY biological products, (no diagnostic substances) | 2.10M | 1.35% | 1.35% | $3.65B | May 27, 2026 | ▲ 720.2K |
UBS GROUP AG biological products, (no diagnostic substances) | 2.00M | 1.29% | 1.29% | $3.48B | Nov 13, 2025 | ▼ 443.1K |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 2.00M | 1.29% | 1.29% | $3.48B | Nov 14, 2025 | ▲ 680 |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 1.37M | 87.92% | 87.92% | $2.38B | Nov 14, 2025 | ▼ 170.8K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 1.15M | 73.78% | 73.78% | $2.00B | Nov 14, 2025 | ▼ 1.41M |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 1.14M | 73.54% | 73.54% | $1.99B | Nov 14, 2025 | ▼ 273.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
18
Increased
+2.66M shares2
New Positions
first time holders23
Decreased
−11.09M shares0
Sold Out
fully exitedNet shares change (top 50)
8.43M
+2.66M / −11.09M
Net new holders
-3
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
HUMA insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
2
Sell transactions
1.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Sebelius Kathleen director | May 19, 2026 | Purchase | 56,818 | $0.88 | $50.0K | 148.0K | Form 4 ↗ |
Constantino Michael T. director | May 18, 2026 | Purchase | 11,000 | $0.89 | $9.8K | 44.0K | Form 4 ↗ |
Sander Dale A. CFO and Chief Corp. Dev. Off | May 18, 2026 | Sale | 45,887 | $0.90 | $41.1K | 267.2K | Form 4 ↗ |
Parikh Shamik J Chief Medical Officer | May 18, 2026 | Sale | 45,887 | $0.90 | $41.1K | 272.7K | Form 4 ↗ |
Sander Dale A. CFO and Chief Corp. Deve. Off. | Nov 16, 2025 | Award | 311,100 | — | — | 313.1K | Form 4 ↗ |
Parikh Shamik J Chief Medical Officer | Nov 16, 2025 | Award | 311,100 | — | — | 318.6K | Form 4 ↗ |
Dougan Brady W director | Nov 16, 2025 | Award | 311,100 | $1.23 | $382.7K | 311.1K | Form 4 ↗ |
Niklason Laura E President, CEO and Director | Nov 16, 2025 | Award | 311,100 | $1.23 | $382.7K | 311.1K | Form 4 ↗ |
Dougan Brady W director | Aug 18, 2025 | Sale | 549,360 | $1.83 | $1.01M | 1.69M | Form 4 ↗ |
Dougan Brady W director | Aug 19, 2025 | Sale | 1,100,000 | $1.63 | $1.79M | 591.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Humacyte, Inc. (HUMA) is primarily owned by institutional investors, who hold approximately 27.3% of total shares outstanding. Company insiders own approximately 17.79%, while retail and public investors account for the remaining 54.91%.
The largest institutional shareholder of Humacyte, Inc. is BLACKROCK, INC., holding approximately 9.90 million shares — equal to 6.37% of outstanding shares — as of September 30, 2025.
A total of 150 institutional investors currently hold HUMA stock, with a combined institutional value of approximately $79,867,842 as of the most recent 13F filing period.
Frequently asked questions
HUMA ownershipHumacyte, Inc. (HUMA) is primarily owned by institutional investors, who hold approximately 27.3% of shares. The largest shareholder is BLACKROCK, INC. with a 6.37% stake. Company insiders hold 17.79%. Data sourced from SEC Form 13F as of September 30, 2025.